SJS Investment Consulting’s Catalyst Pharmaceutical CPRX Stock Holding History

SJS Investment Consulting’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$50	Hold	2	–	–	﹤0.01%	2252
2025 Q4	$47	Hold	2	–	–	﹤0.01%	2025
2025 Q3	$40	Hold	2	–	–	﹤0.01%	1619
2025 Q2	$44	Sell	2 -1	-33%	-$24	﹤0.01%	1522
2025 Q1	$73	Hold	3	–	–	﹤0.01%	1542
2024 Q4	$63	Sell	3 -1	-25%	-$21	﹤0.01%	1549
2024 Q3	$80	Hold	4	–	–	﹤0.01%	1583
2024 Q2	$62	Hold	4	–	–	﹤0.01%	1608
2024 Q1	$64	Sell	4 -1	-20%	-$15	﹤0.01%	1599
2023 Q4	$85	Buy	5 +1	+25%	+$14	﹤0.01%	1564
2023 Q3	$47	Buy	4 +2	+100%	+$27	﹤0.01%	1591
2023 Q2	$27	Hold	2	–	–	﹤0.01%	1577
2023 Q1	$34	Buy	+2	New	+$33	﹤0.01%	1543

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

SJS Investment Consulting's CPRX Position: Q1 2026 in Review

SJS Investment Consulting held its Catalyst Pharmaceutical (CPRX) position steady in Q1 2026 at 2 shares worth $50. The position accounts for ﹤0.01% of the portfolio, ranked #2252.

SJS Investment Consulting first reported a position in CPRX in Q1 2023 and has held it in 13 quarters since. The position peaked at $85 in Q4 2023. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

SJS Investment Consulting held 2 shares of Catalyst Pharmaceutical worth $50 as of Q1 2026.
SJS Investment Consulting left its Catalyst Pharmaceutical share count unchanged in Q1 2026.
Catalyst Pharmaceutical made up ﹤0.01% of SJS Investment Consulting's portfolio in Q1 2026, its #2252 holding.
SJS Investment Consulting first reported a position in Catalyst Pharmaceutical in Q1 2023 and has held it in 13 quarters since.
SJS Investment Consulting's Catalyst Pharmaceutical position peaked at $85 in Q4 2023.
380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on SJS Investment Consulting's 13F filing for Q1 2026, filed 23 Apr 2026.